NHS
Greater Manchester
Cancer Alliance

Renal Cell Carcinoma Pathway

TITLE OF DOCUMENT	GM Renal diagnostic pathway
DATE DOCUMENT PRODUCED	26th September 2025
DOCUMENT VERSION NUMBER	V.1
AUTHOR/S	Dr Tom Waddell, Consultant in Medical Oncology Gastro-Oesophageal and Renal Unit, The Christie Hospital, Manchester Mr Sotonye K Tolofari, Consultant Urological & Robotic Surgeon I Salford Care Organisation
WHICH PROGRAMME / PATHWAY BOARD / GROUP HAS PRODUCED THIS DOCUMENT (IF APPLICABLE)	Greater Manchester Cancer Alliance Urology Pathway Board
WHAT CONSULTATION HAS TAKEN PLACE?	Collaborative working with MSD - to optimise the Renal Cell Carcinoma (RCC) Patient Pathway from diagnosis across all Urology sites in Greater Manchester, East and Mid Cheshire to treatment being given in Oncology at The Christie. Pathway mapping workshops, a GAP analysis workshop and pathway implementation including education developed. This pathway was developed to support the education of the timescales to referral post-surgery. The pathway reflects the national pathway and no changes have been made.
HAS AN EQUALITY IMPACT ASSESSMENT BEEN COMPLETED?	*No – No pathway changes have been made to the national pathway.*
HAVE THE ENVIRONMENTAL SUSTAINABILITY IMPACTS BEEN CONSIDERED AND ADDRESSED?	*No – No pathway changes have been made to the national pathway.*
DATE RATIFIED AT PROGRAMME PATHWAY BOARD	10/02/2026
REVIEW DATE	February 2028

-


Diagnostic to Treatment Pathways
Day 0
Day 1
Day 1 -7
Day 7-14
Day 14-21
Day 21-28
Day 28-62
Referral via ED
Referral via primary care
Referral via Incidental finding (radiology/ward round)
Triage /Scan Request
Outpatient clinic Consultation
Referral
SMDT All referrals to SMDT must have completed pro forma
Suspected / Confirm Cancer Outpatient appropriate to discuss sMDT outcome
Cancer Excluded Patient is discharded/placed under surveillance
Cancer confirmed. Plan discussion with patient. Decision to treat
Diagnostic uncertainty
Biopsy
Robotic partial nephrectomy
Ablative treatment
Radical nephrectomy
Small renal mass (T1A / T1B)
Renal Suspected Cancer (T2+)
Metastatic (M1)
Metastatic, Cytoreductive nephrectomy
Systemic therapy
Supportive care
In line with National Best Time pathway